US-based Glycotest had initially hoped to have the funding round completed by the end of June
Showing 25 of 5482
The ImmunoBody technology was used to develop SCIB1 and SCIB2 – the company’s leading drug candidates.
The approval gives permission for Redx to initiate a Phase IB/ Phase IIA study of RXC004 in patients suffering from gastric, biliary and pancreatic cancer.
Summit wants to improve absorption of ezutromid in patients with duchenne muscular dystrophy (DMD) through a modified diet and new formulation.
Electrical Geodesics has applied to the London Stock Exchange de-list its shares from AIM
Chief executive João Andrade will tell investors the business had made huge strides following its listing around a year ago
“The joint administrators are working with the company's advisers on proposals to rescue Redx and return the company to the control of its directors”
Seppo Mäkinen, Dr Ajay Agrawal and Andrew King bring with them a wealth of industry and commercial experience
Dr David Huang will present at IDWeek 2017 on October 7 where he will give an overview of the REVIVE-1 phase-III clinical study
However, lower overheads should mean that the full-year loss before tax is broadly in line with what it reported last year
Sareum is one of three companies from the UK "Golden Triangle" biotechnology cluster.
Dr Dan Weng joins on July 1 from EPS Holdings, a Tokyo-listed contract research business
CEO Glyn Edwards is to participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference
Dr Jonathan Farr has joined AVO as senior vice president of medical physics with immediate effect
Last month the company received a boost in the form of “constructive feedback” from regulators in both the UK and US reviewing the clinical trial requirements for MED2002.
The loan is repayable by next March, while Ed Lee is the new face among senior management
A large part of the Harley Street treatment room has been manufactured, the patient positioning system is complete and the ionisation chamber has been delivered
WideCells expects its education and training business to be profitable while at the same time driving interest in the group’s other services such as CellPlan
“The company's key priority this year is to move the business through the cash break-even point at the operating level. We have made significant progress towards this goal so far this year.”
The broker adjusted its target for Motif Bio’s shares down to 100p, from 125p previously, with the shares currently trading at 31.25p in late morning trade, down 0.5p on the day
CellPlan is fully authorised to be sold in the UK, Spain and Portugal after it received the necessary approvals from regulators
The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease
The cash will be used to fund the development of Motif’s late-stage antibiotic, iclaprim
The index ranks businesses with the most potential to influence, change or create new global markets
Lupuzor, for the autoimmune disease lupus, is undergoing phase III clinical trials.